Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphoma

Blood (2025) 146 (Supplement 1): 566.

https://doi.org/10.1182/blood-2025-566

Published: 2025

Journal Articles

CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel

Ross McCauley, Amy Zhang, Vamsi Kota, Jacob Boccucci, Michael Grunwald, Matthew Ulrickson, LaQuisa Hill, Ibrahim Muhsen, Joshua Sasine, Anjali Advani, Ibrahim Aldoss, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Silvina Odstrcil Bobillo, Stephanie Tsai, Talal Hilal, Bijal Shah, Rawan Faramand, Jae Park, Yannis Valtis, Tamer Othman, Sumithira Vasu, Evandro Bezerra, Jessica Leonard, Virginia Tan, Kristen O'Dwyer, Jozal Moore, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Wendy Stock, Caspian Oliai, Georgia Lill, Marc Schwartz, Divya Koura, Kaitlyn Dykes, Aaron Logan, Michael Daunov, Ken Byrd, Fevzi Yalniz, Noelle Frey, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Ali Al-Darobi, Evan Chen, Catherine Lee, Timothy O'Connor, Bhagirathbhai Dholaria, Veronika Bachanova, Sean Tracy, Hrishikesh Srinagesh, Katharine Miller, Katherine Sutherland, Navneet Majhail, Luke Mountjoy, Shahbaz Malik, Aravind Ramakrishnan, Paul Shaughnessy, John Mathews, Eunice Wang, Minoo Battiwalla, Gregory Roloff, Lori Muffly

Blood (2025) 146 (Supplement 1): 2396.

https://doi.org/10.1182/blood-2025-2396

Published: 2025

Journal Articles

KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel)

Jessica Leonard, Abdullah Ladha, Rawan Faramand, Gregory Roloff, Yannis Valtis, Virginia Tan, Katharine Miller, Amy Zhang, Michael Grunwald, Vamsi Kota, Jacob Boccucci, Matthew Ulrickson, Ali Al-Darobi, LaQuisa Hill, Ibrahim Muhsen, Joshua Sasine, Anjali Advani, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Evan Chen, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Catherine Lee, Silvina Odstrcil Bobillo, Stephanie Tsai, Timothy O'Connor, Talal Hilal, Jae Park, Sumithira Vasu, Evandro Bezerra, Kristen O'Dwyer, Jozal Moore, Eunice Wang, Ross McCauley, Navneet Majhail, Aravind Ramakrishnan, Luke Mountjoy, Shahbaz Malik, Minoo Battiwalla, Paul Shaughnessy, John Mathews, Hrishikesh Srinagesh, Katherine Sutherland, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Caspian Oliai, Georgia Lill, Wendy Stock, Marc Schwartz, Tamer Othman, Divya Koura, Kaitlyn Dykes, Aaron Logan, Michael Daunov, Ken Byrd, Fevzi Yalniz, Veronika Bachanova, Sean Tracy, Punita Grover, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Bhagirathbhai Dholaria, Noelle Frey, Lori Muffly, Bijal Shah, Ibrahim Aldoss

Blood (2025) 146 (Supplement 1): 3365.

https://doi.org/10.1182/blood-2025-3365

Published: 2025

Journal Articles

Evaluation of commercially available chimeric antigen receptor (CAR) detection reagents for monitoring of CAR T-cell (CAR T) expansion and persistence in patients (pts) treated with obecabtagene autoleucel (obe-cel)

Rehan Hussain, Yousef Farag, Anish Patel, Hrishikesh Srinagesh, Lori Muffly, Bita Sahaf, David Miklos, Mathieu Ferrari, William Day, Pierre Lao-Sirieix

Blood (2025) 146 (Supplement 1): 2367.

https://doi.org/10.1182/blood-2025-2367

Published: 2025

Journal Articles

Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world

Aaron Logan, Fevzi Yalniz, Amy Zhang, Katharine Miller, Katherine Sutherland, Nikeshan Jeyakumar, Hrishikesh Srinagesh, Michael Grunwald, Vamsi Kota, Jacob Boccucci, Matthew Ulrickson, Ali Al-Darobi, Joshua Sasine, LaQuisa Hill, Ibrahim Muhsen, Anjali Advani, Ibrahim Aldoss, Tamer Othman, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Evan Chen, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Catherine Lee, Silvina Odstrcil Bobillo, Stephanie Tsai, Timothy O'Connor, Talal Hilal, Jae Park, Yannis Valtis, Sumithira Vasu, Evandro Bezerra, Eunice Wang, Jessica Leonard, Virginia Tan, Kristen O'Dwyer, Jozal Moore, Ross McCauley, Navneet Majhail, Luke Mountjoy, Aravind Ramakrishnan, Shahbaz Malik, Minoo Battiwalla, Paul Shaughnessy, John Mathews, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Wendy Stock, Gregory Roloff, Caspian Oliai, Georgia Lill, Marc Schwartz, Divya Koura, Kaitlyn Dykes, Michael Daunov, Ken Byrd, Veronika Bachanova, Sean Tracy, Punita Grover, Noelle Frey, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Bhagirathbhai Dholaria, Rawan Faramand, Lori Muffly

Blood (2025) 146 (Supplement 1): 516.

https://doi.org/10.1182/blood-2025-516

Published: 2025

Journal Articles

Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL

Blood (2025) 146 (Supplement 1): 514.

https://doi.org/10.1182/blood-2025-514

Published: 2025

Journal Articles

Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis

Blood (2025) 146 (Supplement 1): 2715.

https://doi.org/10.1182/blood-2025-2715

Published: 2025

Journal Articles

CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity

Blood (2025) 146 (Supplement 1): 4159.

https://doi.org/10.1182/blood-2025-4159

Published: 2025

Journal Articles

CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 2064.

https://doi.org/10.1182/blood-2024-198489

Published: 2024

Journal Articles

CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up

Blood (2024) 144 (Supplement 1): 69.

https://doi.org/10.1182/blood-2024-198544

Published: 2024

Journal Articles

Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms

Blood (2024) 144 (Supplement 1): 96.

https://doi.org/10.1182/blood-2024-205378

Published: 2024

Journal Articles

CD22-Directed CAR T Cell Single Cell Multiomic Features Associated with Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)

Blood (2024) 144 (Supplement 1): 911.

https://doi.org/10.1182/blood-2024-198688

Published: 2024

Journal Articles

A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia

Blood (2024) 144 (16): 1689–1698.

https://doi.org/10.1182/blood.2024024952

Published: 2024

Includes: Supplemental data

Journal Articles

Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL)

Sushma Bharadwaj, Eric Lau, Anmol Goyal, Mark P. Hamilton, Hrishikesh Srinagesh, Alexandria Jensen, Shriya Syal, Jayasindhu Mallampet, Theresa Latchford, Bita Sahaf, Wen-Kai Weng, Melody Smith, Holden T Maecker, Matthew J. Frank, David B. Miklos, Saurabh Dahiya

Blood (2023) 142 (Supplement 1): 4878.

https://doi.org/10.1182/blood-2023-188166

Published: 2023

Journal Articles

CD22 CAR T Cell-Related IEC-HS Is Associated with an IFN-γ Cytokine Signature

Hrishikesh Srinagesh, John H. Baird, Neha Agarwal, Yi-Jiun Su, Anne Marijn Kramer, Agnes Reschke, Nikeshan Jeyakumar, Sushma Bharadwaj, Liora Michal Schultz, Sneha Ramakrishna, Kara L. Davis, Bita Sahaf, Steven Feldman, Crystal L. Mackall, David B. Miklos, Lori S. Muffly, Matthew J. Frank

Blood (2023) 142 (Supplement 1): 4839.

https://doi.org/10.1182/blood-2023-178283

Published: 2023

Journal Articles

The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease

Blood (2019) 134 (Supplement_1): 367.

https://doi.org/10.1182/blood-2019-122011

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphoma

CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel

KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel)

Evaluation of commercially available chimeric antigen receptor (CAR) detection reagents for monitoring of CAR T-cell (CAR T) expansion and persistence in patients (pts) treated with obecabtagene autoleucel (obe-cel)

Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world

Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL

Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis

CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity

CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma

CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up

Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms

CD22-Directed CAR T Cell Single Cell Multiomic Features Associated with Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)

A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia

Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL)

CD22 CAR T Cell-Related IEC-HS Is Associated with an IFN-γ Cytokine Signature

The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only